Finally, Bose et al. showed that the use of an anti-MUC1 antibody inhibited ligand-dependent and -independent mechanisms of anoikis resistance and reduced pancreatic cancer cell survival and invasion in vitro and in a xenograft model [49]. Here, MUC1 is linked to familial pancreatic carcinoma.